Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, HBM Holdings's Enterprise Value is $985.8 Mil.
HBM Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $69.6 Mil. Therefore, HBM Holdings's EV-to-FCF for today is 14.17.
The historical rank and industry rank for HBM Holdings's EV-to-FCF or its related term are showing as below:
HBMHF'
s EV-to-FCF Range Over the Past 10 Years
Min: -17.19 Med: -0.03 Max: 52.47
Current: 14.55
During the past 8 years, the highest EV-to-FCF of HBM Holdings was 52.47. The lowest was -17.19. And the median was -0.03.
HBMHF's EV-to-FCF is ranked better than 52.02% of 346
companies
in the Biotechnology industry
Industry Median: 14.31
vs HBMHF: 14.55
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HBM Holdings's PE Ratio (TTM) for today is calculated as:
HBM Holdings's share price for today is $1.56.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
HBM Holdings EV-to-FCF Related Terms
HBM Holdings EV-to-FCF Historical Data
* Premium members only.
The historical data trend for HBM Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HBM Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where HBM Holdings's EV-to-FCF falls into.
HBM Holdings's current Enterprise Value is $985.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $69.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (HBMHF) has a EV-to-FCF of 14.17 as of Jul. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on HBM Holdings and its competitors. According to the industry distribution chart, HBM Holdings ranks #166 out of 346 companies in the Biotechnology industry, placing it in the top 48%.
Is HBM Holdings' EV-to-FCF too high?
HBM Holdings' current EV-to-FCF is 14.17. The Biotechnology industry median EV-to-FCF is 14.31. HBM Holdings' value of 14.17 is 1% below this industry median. Based on the distribution chart, HBM Holdings ranks #166 out of 346 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HBM Holdings has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #166 out of 346 companies for EV-to-FCF. This puts HBM Holdings in the upper half of its industry. The industry median EV-to-FCF is 14.31. HBM Holdings' value of 14.17 is 1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.31, based on 346 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HBM Holdings's current EV-to-FCF of 14.17 is 1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on HBM Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HBM Holdings's current EV-to-FCF is 14.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
HBM Holdings (HBMHF) has a current EV-to-FCF of 14.17. The stock's GF Value™ is $0.87, compared to a current price of $1.56 — trading 79.3% above its estimated fair value. The current EV-to-FCF is 14.17 and 1% below the Biotechnology industry median of 14.31. HBM Holdings' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For HBM Holdings (HBMHF), the current EV-to-FCF is 14.17 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (HBMHF) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of $1.56 is trading 79.3% above its estimated GF Value™ of $0.87.
Key valuation signals for HBMHF:
EV-to-FCF: 14.17
GF Value™: $0.87 vs. price of $1.56 (79.3% above fair value)
Industry Position: 1% below the Biotechnology median (#166 of 346)
No single metric tells the full story. See the HBMHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
73GF Score
Get the complete analysis for HBMHF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBMHF has been successfully added to your 
